Parliament backs 50% local content rule for critical drugs, but member states balk at ambitious manufacturing requirements.
ℹ️ Browser-based reading · AI studio voice coming soon
The European Union is struggling to align on new pharmaceutical manufacturing rules as it seeks to strengthen drug supply security and reduce dependence on imports, according to EurActiv.
The European Parliament has advocated for requiring at least 50% of key ingredients or production value to originate within the EU for critical medicines. However, member states have resisted the scope and stringency of the proposal.
The divergence reflects competing economic interests: some capitals worry strict local-content mandates will increase drug costs and production timelines, while others prioritize supply chain resilience following pandemic shortages. The debate comes as the EU develops a strategy to boost its pharmaceutical manufacturing capacity and reduce vulnerability to external supply disruptions.
The EU Parliament wants 50% of critical drug ingredients made locally to boost supply security, but member states are blocking the rule, fearing it will raise medicine costs and slow production. The clash reflects deeper disagreements over whether manufacturing resilience or affordability should take priority.
If local-content rules pass, your prescription medicines could become more expensive and harder to access quickly—but if they don't, drug shortages like those during COVID could hit Europe again. Your healthcare costs and the reliability of essential medicines hang on how this regulatory standoff is resolved over the coming months.